Every year, women with fibroids lose their uteruses during C-sections because the surgical team was reacting instead of prepared. The information to prevent it existed. No one connected it in time.
Women with fibroids face significantly elevated risks during C-section delivery, including postpartum hemorrhage and emergency hysterectomy. These risks are not always unpredictable. Prenatal ultrasounds taken weeks before delivery document fibroid size, location, and vascularity. That data rarely reaches the surgical team in a form they can act on.
The result, in many cases, is a surgical team that is reacting to a crisis rather than prepared for one. The difference between those two situations can determine whether a woman leaves the operating room with her uterus intact.
"The scans exist. The protocols exist. The knowledge exists. What is missing is the system that connects them before delivery, not after hemorrhage begins."
FibroidSafe is a pre-product concept in active clinical validation. This is what the system is designed to do, described in plain terms for the clinicians and partners we are seeking to work with.
The system would connect to a hospital's existing imaging infrastructure and pull prenatal ultrasounds already on file. AI would analyze fibroid size, location, vascularity, and position relative to the lower uterine segment. No new hardware. No new scans.
Concept stageThe AI would generate a hemorrhage risk score based on the fibroid characteristics that existing research identifies as most predictive of intraoperative bleeding. The scoring model is what we are currently seeking clinical input to validate.
Seeking validationA high-risk score would automatically trigger a prep checklist to the right people before the delivery date: blood bank crossmatch, IR on standby, cell saver staged, surgeon fibroid map delivered. The goal is preparation, not diagnosis.
In designThe tools exist. The data exists. The clinical need is documented. FibroidSafe is designed to be a system that connects them specifically for fibroid-related obstetric hemorrhage risk. To our knowledge, no equivalent system currently exists, though we are actively seeking clinical input to validate that assessment.
Women with uterine fibroids face an 80% higher likelihood of cesarean delivery, creating a large, identifiable population with elevated surgical risk.
Women with fibroids face nearly three times the risk of postpartum hemorrhage compared to those without, with risk increasing with fibroid size and location.
Designed to integrate with existing EHR and PACS infrastructure. No capital equipment. Subject to clinical and regulatory validation.
FibroidSafe was not born in a lab or a business school. It was born on an operating table.
The founder experienced an emergency hysterectomy during a C-section because of fibroids. Her son was born into a room where his mother's body was fighting for survival because the right information never reached the right people in time.
She spent five years sitting with that. Then she decided to build the system that should have existed.
That is what FibroidSafe is. Not a research project. Not a market opportunity. A decision that no other family should go through what hers did because the data existed and no one connected it.
"The scans were there. The risk was visible in the imaging weeks before I delivered. Nobody read them looking for what was coming. I am building the system that does."Founder, FibroidSafe. Patient, 2021.
FibroidSafe is pre-product and in active clinical validation. We are not looking for investors yet. We are looking for people who know this space and can help us get the foundations right.
hello@fibroidsafe.comWe are at the clinical validation stage. A few sentences about who you are and why you are here is all we need to start a conversation.